Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,069
Employees1,069
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,069
Employees1,069

IONS Key Statistics

Market cap
12.33B
Market cap12.33B
Price-Earnings ratio
-44.46
Price-Earnings ratio-44.46
Dividend yield
Dividend yield
Average volume
4.11M
Average volume4.11M
High today
$76.31
High today$76.31
Low today
$72.04
Low today$72.04
Open price
$73.05
Open price$73.05
Volume
2.05M
Volume2.05M
52 Week high
$76.78
52 Week high$76.78
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $76.09. The company's market cap stands at 12.33B, with a P/E ratio of -44.46.

On 2025-11-22, Ionis Pharmaceuticals(IONS) stock moved within a range of $72.04 to $76.31. With shares now at $76.09, the stock is trading +5.6% above its intraday low and -0.3% below the session's peak.

Trading activity shows a volume of 2.05M, compared to an average daily volume of 4.11M.

The stock's 52-week range extends from a low of $23.95 to a high of $76.78.

The stock's 52-week range extends from a low of $23.95 to a high of $76.78.

IONS News

Simply Wall St 1d
Did Breakthrough CHMP Opinion and Phase 3 Data Just Shift Ionis Pharmaceuticals' Investment Narrative?

Earlier this month, Ionis Pharmaceuticals and partner Otsuka Pharmaceuticals announced that the European Medicines Agency’s CHMP adopted a positive opinion for...

Did Breakthrough CHMP Opinion and Phase 3 Data Just Shift Ionis Pharmaceuticals' Investment Narrative?
TipRanks 2d
Director’s Multi-Million Dollar Stock Sale Shakes Ionis Pharmaceuticals

New insider activity at Ionis Pharmaceuticals ( (IONS) ) has taken place on November 20, 2025. TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the...

Analyst ratings

74%

of 23 ratings
Buy
73.9%
Hold
26.1%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.